Biosimilars have been around for nearly a decade, but with Humira's list price of around $7,000, biosimilars for the drug are making an incredible splash in the pharmacy industry. With several biosimilars already launched in 2025 and more in the pipeline, many plan sponsors are wondering how to navigate the integration of these products into their pharmacy benefit strategies. In this episode, Employers Health's Mike Stull chats with Jeff Casberg, head of clinical pharmacy at IPD Analytics to discuss all things biosimilars, including how biosimilar launch dates and pricing are determined, cost savings associated with these products, the importance of biosimilar formulary positioning and more. Want to hear more from Jeff? Join us at the Annual Benefits Forum April 22-23 in Columbus, Ohio, where he'll present "The Impact of New Drugs and Therapies on PBM Spend."